Sunshine Biopharma Inc.: 10-Q filed 2022-11-07

Name: Sunshine Biopharma Inc.: 10-Q filed 2022-11-07
Creator: Sunshine Biopharma Inc.

What Sunshine Biopharma Inc. reported in its quarterly report filed 2022-11-07 (fiscal Q3 2022): 36 published measures, 108 facts as tagged in accession 0001683168-22-007290.

This filing

Form: 10-Q (quarterly report)
Filed: 2022-11-07
Fiscal period: fiscal Q3 2022
Accession: 0001683168-22-007290 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Sunshine Biopharma Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2022-09-30	40,864,344	USD
At 2021-12-31	2,202,891	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2022-09-30	480,209	USD
At 2021-12-31	1,991,229	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2022-09-30	40,384,135	USD
At 2022-06-30	41,886,280	USD
At 2021-12-31	211,662	USD
At 2021-09-30	-1,173,932	USD
At 2021-06-30	-872,710	USD
At 2020-12-31	-954,837	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2022-09-30	40,555,931	USD
At 2021-12-31	2,045,167	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-1,457,019	USD	92
2022-01-01 to 2022-09-30	-3,232,125	USD	273
2021-07-01 to 2021-09-30	-4,039,383	USD	92
2021-01-01 to 2021-09-30	-13,103,563	USD	273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-3,001,746	USD	273
2021-01-01 to 2021-09-30	-1,517,015	USD	273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	132,808	USD	92
2022-01-01 to 2022-09-30	405,760	USD	273
2021-07-01 to 2021-09-30	50,376	USD	92
2021-01-01 to 2021-09-30	143,308	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	41,561,363	USD	273
2021-01-01 to 2021-09-30	2,928,339	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-09-30	-35,887,299	USD
At 2021-12-31	-32,655,174	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	18,885,632	shares	92
2022-01-01 to 2022-09-30	12,789,733	shares	273
2021-07-01 to 2021-09-30	2,542,640	shares	92
2021-01-01 to 2021-09-30	2,287,682	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-0.08	USD/shares	92
2022-01-01 to 2022-09-30	-0.26	USD/shares	273
2021-07-01 to 2021-09-30	-1.59	USD/shares	92
2021-01-01 to 2021-09-30	-5.73	USD/shares	273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Unit	Days
2022-07-01 to 2022-09-30	USD	92
2022-01-01 to 2022-09-30	USD	273
2021-07-01 to 2021-09-30	USD	92
2021-01-01 to 2021-09-30	USD	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2022-09-30	3,770	USD
At 2021-12-31	7,061	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-1,717,980	USD	92
2022-01-01 to 2022-09-30	-3,637,140	USD	273
2021-07-01 to 2021-09-30	-496,259	USD	92
2021-01-01 to 2021-09-30	-2,160,503	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2022-09-30	40,860,574	USD
At 2021-12-31	2,195,830	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	2	USD	92
2022-01-01 to 2022-09-30	12,866	USD	273
2021-07-01 to 2021-09-30	46,849	USD	92
2021-01-01 to 2021-09-30	292,188	USD	273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2022-09-30	480,209	USD
At 2021-12-31	91,229	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2022-09-30	480,209	USD
At 2021-12-31	42,942	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2022-09-30	22	USD
At 2021-12-31	7,798	USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2022-09-30	269,641	USD
At 2021-12-31	105,650	USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	67,025	USD	92
2022-01-01 to 2022-09-30	205,449	USD	273
2021-07-01 to 2021-09-30	30,870	USD	92
2021-01-01 to 2021-09-30	86,767	USD	273

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	65,783	USD	92
2022-01-01 to 2022-09-30	200,311	USD	273
2021-07-01 to 2021-09-30	19,506	USD	92
2021-01-01 to 2021-09-30	56,541	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	362,500	USD	92
2022-01-01 to 2022-09-30	770,095	USD	273
2021-07-01 to 2021-09-30	222,465	USD	92
2021-01-01 to 2021-09-30	581,011	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2022-09-30	18,885,632	shares
At 2021-12-31	2,591,240	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2022-09-30	40,555,931	USD
At 2021-12-31	2,045,167	USD
At 2021-09-30	2,386,608	USD
At 2020-12-31	989,888	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2022-09-30	76,331,451	USD
At 2021-12-31	32,787,384	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2022-09-30	-79,903	USD
At 2021-12-31	-23,139	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-1,457,019	USD	92
2022-01-01 to 2022-09-30	-3,232,125	USD	273
2021-07-01 to 2021-09-30	-4,039,383	USD	92
2021-01-01 to 2021-09-30	-13,103,563	USD	273

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-1,502,145	USD	92
2022-01-01 to 2022-09-30	-3,288,889	USD	273
2021-07-01 to 2021-09-30	-4,045,222	USD	92
2021-01-01 to 2021-09-30	-13,118,167	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	1,785,005	USD	92
2022-01-01 to 2022-09-30	3,842,589	USD	273
2021-07-01 to 2021-09-30	527,129	USD	92
2021-01-01 to 2021-09-30	2,247,270	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	789	USD	92
2022-01-01 to 2022-09-30	6,186	USD	273
2021-07-01 to 2021-09-30	3,183	USD	92
2021-01-01 to 2021-09-30	9,557	USD	273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	260,961	USD	92
2022-01-01 to 2022-09-30	405,015	USD	273
2021-07-01 to 2021-09-30	-3,543,124	USD	92
2021-01-01 to 2021-09-30	-10,943,060	USD	273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	61,151	USD	273
2021-01-01 to 2021-09-30	155,081	USD	273

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	0	USD	273
2021-01-01 to 2021-09-30	0	USD	273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-7,776	USD	273
2021-01-01 to 2021-09-30	-787	USD	273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	163,991	USD	273
2021-01-01 to 2021-09-30	47,539	USD	273

Inspect the source

Entity: Sunshine Biopharma Inc. / CIK 0001402328
Captured: 2026-09-20T08:00:47.083Z
SEC response SHA-256: 089eb69bd01c2bc993f5073ccdb651eba31ddb7f7ea640d657095dcd4ddd9932

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001402328.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))